May 18, 2026 08:01AM
May 18, 2026 08:00AM
Apr 21, 2026 08:31AM
Apr 21, 2026 08:30AM
Mar 23, 2026 08:00AM
Mar 23, 2026 08:00AM
Jan 23, 2026 08:01AM Enlivex Therapeutics to delist from Tel Aviv exchange, focus on NASDAQ
Jan 23, 2026 08:00AM
Nov 26, 2025 08:00AM
Nov 26, 2025 08:00AM
Nov 24, 2025 10:00AM
Nov 24, 2025 10:00AM
Sep 19, 2025 09:00AM
Sep 11, 2025 08:01AM Enlivex CEO outlines roadmap after knee arthritis trial results
Sep 11, 2025 08:00AM
Mar 3, 2025 08:23AM
Mar 3, 2025 08:22AM
Jul 19, 2024 09:00AM
Jun 11, 2024 06:42AM
May 28, 2024 08:12AM
May 28, 2024 08:12AM Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
Feb 21, 2024 08:30AM
Nov 21, 2023 07:00AM
Feb 15, 2023 08:00AM
Dec 5, 2022 08:00AM
Nov 28, 2022 08:03AM
Nov 28, 2022 08:00AM
Sep 6, 2022 08:08AM Enlivex Therapeutics (ENLV) Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome in Patients Receiving CAR T Cell Therapy
Sep 6, 2022 08:00AM
Aug 24, 2022 08:00AM
Aug 22, 2022 08:00AM
Jul 6, 2022 08:36AM
Jun 6, 2022 08:00AM
May 9, 2022 09:05AM
Apr 29, 2022 08:41AM Enlivex Announces Full Year 2021 Financial Results, Completion of Development of Frozen Formulation Allocetra™ Ahead of Schedule, and Provides Strategic & Business Updates
Feb 22, 2022 08:00AM
Nov 22, 2021 08:00AM
Aug 9, 2021 08:00AM
Aug 2, 2021 08:00AM
Dec 21, 2020 08:09AM
Dec 21, 2020 08:00AM
Nov 17, 2020 08:18AM Enlivex Appoints Former ArQule, Inc. Executive Dr. Brian Schwartz to the Company’s Board of Directors
Oct 1, 2020 09:30AM
Aug 25, 2020 09:30AM
Mar 18, 2020 08:04AM
Mar 18, 2020 08:00AM
Mar 18, 2020 08:00AM
Mar 2, 2020 09:24AM
Nov 18, 2019 08:36AM Enlivex Therapeutics Ltd. (ENLV) Reports Complete Recruitment in Ph. Ib Trial Evaluating Safety & Efficacy of Universal Off-The-Shelf Allocetra in Patients With Severe Sepsis
Nov 18, 2019 08:30AM

322,861 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All